Clinical trials: Renal Cell Cancer Metastatic
Prostate Cancer, Renal Cancer
64Cu-GRIP B in Patients With Advanced Malignancies
This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET)…
- Conditions
- Prostate Cancer, Renal Cancer, Urethral Cancer, Advanced Solid Tumor
- Trial name
- NCT05888532
- Testing
- Copper-64 labeled Granzyme B (64Cu-GRIP B), Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Rahul Aggarwal
Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system.
- Trial name
- NCT02655822
- Testing
- Ciforadenant, Ciforadenant + atezolizumab
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 502 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Renal Cell Carcinoma
A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
This is a Phase 2 clinical trial to collect data on tumor responses produced by folate-hapten conjugate therapy (vaccination with EC90 [KLH-FITC] and GPI-0100 adjuvant followed by treatment with EC17 (folate-FITC) in combination…
- Trial name
- NCT00485563
- Testing
- EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC)
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Endocyte
Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
Phase II trial to study the effectiveness of ixabepilone in treating patients who have progressive or metastatic urinary tract cancer.
- Conditions
- Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer
- Trial name
- NCT00021099
- Testing
- ixabepilone
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Merkel Cell Carcinoma, Unspecified
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to evaluate whether zirconium Zr 89 crefmirlimab berdoxam (other names 89Zr-crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C) PET/CT can predict the response of advanced or metastatic…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Unspecified, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- iPREDICT (NCT05013099)
- Testing
- zirconium Zr 89 crefmirlimab berdoxam
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 70 people
- Sponsor
- ImaginAb, Inc.
Breast Cancer, Renal Cell Carcinoma
Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma
MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells…
- Trial name
- MARIO-3 (NCT03961698)
- Testing
- IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel
- Where
- 24 sites in United States
- Volunteers
- 91 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Carcinoma, Renal Cell
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
To assess the maximum tolerated dose and overall safety and tolerability of sunitinib [SU011248] administered in combination with gefitinib (Iressa) for the treatment of patients with metastatic renal cell carcinoma (Phase 1).
- Trial name
- NCT00113529
- Testing
- Gefitinib + Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pfizer
Kidney Cancer
Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Interferon alfa may interfere with the growth of the cancer cells and slow the growth of kidney cancer. Isotretinoin may help kidney cancer cells develop into normal cells.
- Trial name
- NCT00002737
- Testing
- recombinant interferon alfa, chemotherapy, isotretinoin
- Where
- 27 sites in Belgium, Hungary and 7 more
- Volunteers
- 320 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Locally Advanced or Metastatic Renal Cell Carcinoma
Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors
To understand the epidemiology, treatment patterns and outcomes of patients with metastatic Renal Cell Carcinoma (mRCC). Data from mRCC patients who received cabozantinib versus non-cabozantinib Tyrosine Kinase Inhibitor (TKI) (a…
- Trial name
- US NIS Cabo (NCT04353765)
- Testing
- Cabozantinib monotherapy, All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC
- Where
- United States
- Volunteers
- 247 people
- Sponsor
- Ipsen
Clear Cell Renal Carcinoma
TroVax Renal Immunotherapy Survival Trial
The purpose of this study is to investigate whether TroVax, when added to first line standard of care therapy, improves survival for patients with locally advanced or metastatic clear cell renal adenocarcinoma.
- Trial name
- NCT00397345
- Testing
- Trovax, Standard of care therapy
- Where
- 152 sites in United States, France and 8 more
- Volunteers
- 733 people
- Sponsor
- Oxford BioMedica
Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
This phase I trial tests the safety, side effects, best dose, and effectiveness of CBM588 in combination with nivolumab and ipilimumab in treating patients with kidney cancer that may have spread from where it first started to…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- NCT06399419
- Testing
- Biospecimen Collection, Bone Scan, CBM588 Capsules
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Osel, Inc.
Kidney Cancer
Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00243009
- Testing
- cyclosporine, fludarabine phosphate, mycophenolate mofetil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- OHSU Knight Cancer Institute
Renal Cell Carcinoma, Circulating Tumor Cell
Circulating Tumor Cell Reducing No-touch Nephrectomy
This study will study circulating tumor cell (CTC) release during laparoscopic radical nephrectomy (LRN) for RCC. The main objective is to determine if CTC release can be reduced during RN by using a no-touch technique, with an…
- Trial name
- CITO-CERENE (NCT05070637)
- Testing
- No-touch laparoscopic radical nephrectomy, Conventional laparoscopic radical nephrectomy, Laparoscopic total nephrectomy control arm
- Where
- Portugal
- Volunteers
- 44 people
- Sponsor
- Hospital de Santa Maria, Portugal
Chronic Myeloproliferative Disorders, Kidney Cancer
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
RATIONALE: Light-emitting diode (LED) therapy may be able to prevent mucositis of the mouth. PURPOSE: Randomized phase II trial to determine the effectiveness of LED therapy in preventing mucositis of the mouth in children who…
- Conditions
- Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00036712
- Testing
- management of therapy complications, pain therapy
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Medical College of Wisconsin
Renal Cell Carcinoma, First-line Treatment
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
This is a Phase Ib/II, open-label, single arm trial to evaluate the efficacy and safety of AK104 in combination with axitinib as a first-line treatment for advanced/metastatic special pathological subtypes of renal cell carcinoma…
- Conditions
- Renal Cell Carcinoma, First-line Treatment, Non Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
- Trial name
- NCT05808608
- Testing
- AK104, Axitinib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Hao Zeng
Complete Remission in Renal Cell Carcinoma
Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients
This prospective study will investigate the characteristics of mRCC patients at time of CR in comparison with mRCC patients non on CR treated with Sunitinib, in order to provide some answers/ refection leads to the following…
- Trial name
- APERCU (NCT01934452)
- Testing
- sunitinib
- Where
- 14 sites in France
- Volunteers
- 77 people
- Sponsor
- Pfizer
Metastatic Clear Cell Renal Cell Carcinoma
Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
Nivolumab (brand name Opdivo): IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist, until disease progression or unacceptable toxicity; SABR, dose…
- Trial name
- NCT02781506
- Testing
- Nivolumab, SAbR
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Texas Southwestern Medical Center
Advanced or Metastatic Solid Tumor
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab…
- Trial name
- NCT06270706
- Testing
- PLN-101095, Pembrolizumab
- Where
- 22 sites in United States, Spain
- Volunteers
- 124 people
- Sponsor
- Pliant Therapeutics, Inc.
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
This randomized phase III trial studies how well pazopanib hydrochloride works compared to placebo in treating patients with kidney cancer that has spread to other parts of the body and have no evidence of disease after surgery.
- Trial name
- NCT01575548
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Pazopanib Hydrochloride
- Where
- 579 sites in United States
- Volunteers
- 129 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.